FORM 4

to Section 16. Form 4 or Form 5 obligations may continue. See

Instruction 1(b).

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, I	D.C. 20549	
---------------	------------	--

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Check this box if no longer subject

OMB APPROVAL										
OMB Number: 3235-028										
Estimated average burden										
hours per response:	0.5									

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Fleming Alison B				2. Issuer Name and Ticker or Trading Symbol COLLEGIUM PHARMACEUTICAL, INC [ COLL ]									ck all app Direc	,	ng Pers	10% O	wner			
(Last)	(Fi	rst) (M	Middle)		3. Da	Date of Earliest Transaction (Month/Day/Year)								^	pelov	v) nief Techn	റിറ്റേ	below)		
C/O COLLEGIUM PHARMACEUTICAL, INC.				08/10/2020									O.	ner reemi	ology	Officer				
100 TECHNOLOGY CENTER DRIVE																				
(Street)					4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)								Line)	Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person					
\$100GI	HTON M.	A 0	2072													filed by Moi	re thar	n One Rep	orting	
(City)	(St	ate) (2	Zip)												Perso	Off				
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3)  2. Transact Date (Month/Day						Execution Dat		Date,	Transaction Disp Code (Instr. 5)		Disposed C	Securities Acquired (A sposed Of (D) (Instr. 3,			5. Amo Securit Benefic Owned Report	ties cially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	Amount	(A) (D)	or P	rice	Transa	ction(s) 3 and 4)			(					
Common Stock 08/10/2					2020			F		1,515 <sup>(1)</sup>	Г	\$	18.89	10	101,386		D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	erivative Conversion Date Execution Date, ecurity or Exercise (Month/Day/Year) if any				Transaction of Code (Instr. 8) Se Ac (AA Dii of		osed ) r. 3, 4	6. Date Exerci Expiration Da (Month/Day/Y		ite	7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		Str.	Price of erivative ecurity istr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Owner Form: Direct or Ind (I) (Ins	Ownership	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code		v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Numl of Share							

## **Explanation of Responses:**

1. Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units.

## Remarks:

/s/ Paul Brannelly as Attorney-08/1<u>2/2020</u> In-Fact For Alison B. Fleming

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.